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Lay abstract 
One hypothesis about the causation of autism is dependent on the theory of a ‘leaky gut’ that 
causes increased permeability to substances harmful to the brain. Some studies have found 
increased gut permeability in autism, others have not. Many studies have found increased 
reported symptoms of gastrointestinal dysfunction in autism. We measured gut permeability 
using a technique of sugar absorption from the gut and excretion in the urine. We did this in 
two groups of children, one with autism spectrum disorder (ASD) and one with special 
educational needs (SEN) from a variety of causes but no ASD. A few children (11 of 133) 
across both groups had some evidence of increased gut permeability, only 2 children at 
‘pathological levels’, but there was no difference in the proportions in each group. The 2 
children with definite increased gut permeability both had disorders of gut function which 
made the increased permeability explicable. We concluded that permeability is not increased 
in the majority of children aged 10-12 years with ASD compared with other groups of similar 
ages who have special educational needs.  
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Scientific Abstract 
OBJECTIVE: To test whether gut permeability is increased in autism spectrum disorders 
(ASD) by evaluating gut permeability in a population-derived cohort of children with ASD 
compared with age- and IQ-matched controls without ASD but with special educational 
needs (SEN).  
PATIENTS AND METHODS: 133 children aged 10-14 years, 103 with ASD and 30 with 
SEN, were given an oral test dose of mannitol and lactulose and urine collected for 6h. Gut 
permeability was assessed by measuring the urine lactulose/mannitol (L/M) recovery ratio by 
electrospray mass spectrometry-mass spectrometry. The ASD group was sub-categorised for 
comparison into those without (n=83) and with (n=20) regression. 
RESULTS: There was no significant difference in L/M recovery ratio (mean (95% 
confidence interval)) between the groups with ASD: 0.015 (0.013-0.018), and SEN: 0.014 
(0.009-0.019); nor in lactulose, mannitol, or creatinine recovery. No significant differences 
were observed in any parameter for the regressed versus non-regressed ASD groups. Results 
were consistent with previously published normal ranges. Eleven children (9/103=8.7% ASD 
and 2/30=6.7% SEN) had L/M recovery ratio >0.03 (the accepted normal range cut-off), of 
whom two  (1 ASD and 1 SEN) had more definitely pathological L/M recovery ratios >0. 04.  
CONCLUSION: There is no statistically significant group difference in small intestine 
permeability in a population cohort-derived group of children with ASD compared with a 
control group with SEN.  Of the two children (1 ASD and 1 SEN)  with an L/M recovery 
ratio of >0.04, one had undiagnosed asymptomatic coeliac disease (ASD) and the other past 
extensive gastroschisis surgery (SEN).   
 
 
Key Words: autism, autism spectrum disorders, gut permeability, lactulose/mannitol ratio 
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Introduction 
 
One of the hypotheses implicated in the pathogenesis of autism has been the suggestion that 
autism “may be caused by endogenous overactivity of the child’s own brain opiate system” 
[Panksepp, 1979].  This was followed by data indicating abnormal peptides, “capable of 
modulating the function of major neurotransmitters”, in the urine of patients with autism 
[Reichelt et al., 1981].  These ideas and observations led to the “leaky gut” theory of autism 
in which “toxic” peptides with opioid activity derived from incomplete breakdown of foods, 
particularly casein and gluten, are absorbed, cross the blood-brain barrier and cause autism 
[Le Couteur, Trygstad, Evered, Gillberg, & Rutter, 1988; Panksepp, 1979; Reichelt et al., 
1981; Shattock & Lowdon, 1991; Shattock & Whiteley, 2002]. The proposition is that, as a 
result of gastrointestinal inflammation, also causing gastrointestinal symptoms (GIS), the 
normal barrier to peptide absorption from the gut is compromised. Increased rates (22-70%) 
of GIS have been reported in ASD [Chandler et al., 2013; Erickson, Stigler, Corkins, Posey, 
Fitzgerald, & McDougle, 2005; Gorrindo, Williams, Lee, Walker, McGrew, & Levitt, 2012; 
Horvath & Perman, 2002; Smith, Farnworth, Wright, & Allgar, 2009;  Valicenti-McDermott, 
McVicar, Rapin, Wershil, Cohen, & Shinnar, 2006; Wang, Tancredi, & Thomas, 2011],
 
a 
variability that may depend on the sample (clinical or population-derived); the type, 
definition and number of symptoms; the method of investigation employed; and whether 
symptoms are current or life-time. The GIS most commonly reported in ASD are diarrhoea 
(loose frequent stools), constipation, and abdominal discomfort/pain. The American 
Academy of Pediatrics (AAP) consensus report
 
[Buie et al., 2010a] found no conclusive 
evidence of a unique gastrointestinal pathophysiology specific to autism and related 
disorders.    
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Several reports have described increased gut permeability in children with autism [De 
Magistris et al., 2010; D’Eufemia et al., 1996; Horvath, Zielke, Collins, Rabsztyn, Medeiros, 
& Perman, 2000; Liu, Li, & Neu, 2005] and there has been considerable promotion of dietary 
manipulation, particularly of casein and gluten, in the treatment of autism [Knivsberg, 
Reichelt, Hoien, & Nodland, 2002; Levy & Hyman, 2008; Millward, Ferriter, Calver, & 
Connell-Jones, 2004; Reichelt, Ekrem, & Scott, 1990]. However, it is important to emphasise 
that the fundamental basis of the “leaky gut” hypothesis does not rely on either the presence 
of inflammation or confirming neuropeptides in the urine, but on demonstrating impaired gut 
permeability in children with ASD; and the most recent consensus report of the AAP clearly 
highlights the limited evidence for abnormal gastrointestinal permeability in individuals with 
autism and recommends properly powered studies with appropriate controls to determine the 
role of abnormal permeability in ASD [Buie et al., 2010b].  
 
We took advantage of a population-based epidemiological study of ASD [Baird et al., 2006] 
to perform formal gut permeability studies in as many participants as possible. Children with 
ASD were compared with children with other developmental disorders but without ASD. 
Contemporaneously, parents were asked to complete a questionnaire about current and past 
gastro-intestinal symptoms and evidence of coeliac disease was sought. Ethical permission 
was granted by the South Thames research ethics committee (MREC 00/1/50). 
 
Patients and methods 
Patients 
The sampling methodology of the SNAP study has been described previously [Baird et al., 
2006].  In brief, within a total population cohort of 56,946 children born between July 1
st
 
1990 and December 31
st
 1991, all with a current clinical diagnosis of ASD (N=255) or 
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considered ‘at risk’ by virtue of having a Statement of Special Educational Needs1 (SEN; 
N=1,515) were screened using the Social Communication Questionnaire (SCQ) [Rutter, 
Bailey, & Lord, 2003]. 
 
A stratified subsample (by coincidence also N=255) based on SCQ 
score received a comprehensive diagnostic assessment including standardized clinical 
observation (Autism Diagnostic Observation Schedule – Generic (ADOS-G)) [Lord et al., 
2000], parent interview assessments of autistic symptoms (Autism Diagnostic Interview-
Revised (ADI-R)) [Lord, Rutter, & Le Couteur, 1994], intelligence (intelligence quotient, 
IQ), and a medical examination. There were no exclusion criteria.  ADI-R and ADOS-G 
information was used to derive a clinical consensus diagnosis of ASD (childhood autism and 
other ASDs: atypical autism, pervasive developmental disorder) with reference to ICD-10 
research criteria.  Severity of autism was measured in terms of number of ICD-10 symptoms 
(0-12). Regression was defined as a loss of 5 words used communicatively for 3 months 
before loss or, where the child had not reached the 5-word stage, as loss of words or babble 
with regression of social and play skills [Baird et al., 2008].  Cases not meeting criteria for a 
diagnosis of ASD were categorized as SEN; these children had special educational needs and 
a variety of other diagnoses including attention deficit hyperactivity disorder (ADHD), 
cerebral palsy, language disorders and intellectual disability [Baird et al., 2008].   
 
Cognitive function was established using the Wechsler Intelligence Scale for Children-III-UK 
(WISC) [Wechsler, 1992], Raven’s Standard Progressive Matrices (SPM) [Raven, Court, & 
Raven, 1990a] or Coloured Progressive Matrices (CPM) [Raven, Court, & Raven, 1990b], 
depending on the child’s ability. For children for whom SPM or CPM but not WISC full-
scale IQs were available, imputed full-scale IQs were obtained using the regression 
relationship of full-scale IQ to SPM/CPM within each diagnostic group.  
                                                 
1
A Statement of Special Educational Needs is a legal document issued by the local educational authority when 
children require significant additional support in school due to any learning and/or behavioural problems.  
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A blood sample was taken, with consent, from 173 of 255 of those in the ASD and SEN 
groups and a number of analyses performed. Where there was sufficient blood, a standard 
diagnostic assay of anti-endomysial IgA and anti-gliadin IgA was carried out, in a certified 
laboratory.  
 
Gastro-Intestinal Symptoms (GIS) 
Parental report on GIS was collected at the time of the diagnostic assessment using a 
questionnaire administered by researcher interview with the parents/carers of the ASD and 
SEN participants. A 20-item GIS questionnaire was constructed about current (last three 
months) and past (prior to the last three months) symptoms [Chandler et al., 2013]. The GIS 
included: persistent vomiting (at least once per day or more than five times in a  week); stool 
consistency (formed, watery or mushy); abdominal pain (three or more episodes severe 
enough to interfere with activity); abdominal pain associated with food, bowel movement or 
sleep; constipation (decreased frequency of bowel movement to less than three times a week 
in the last three months); and associated symptoms such as subjective difficulties with bowel 
movement and harder consistency of stools; stool withholding and soiling; diarrhoea 
(loose/watery stools three or more times a day); weight loss; mouth ulcer; presence of mucus 
or blood in the stools. Sub-items of the current and past diarrhoea questions established 
chronicity with persistent diarrhoea being defined as lasting more than 14 days.   'Possible 
enterocolitis' was defined as the presence of 2 or more of 4 current GIS: persistent diarrhoea, 
weight loss, abdominal pain or blood in stool plus past persistent diarrhoea and excluding 
current constipation. 
Parents of children with ASD and SEN were asked to record their child’s typical diet for three 
days (including main meals, snacks and drinks over two weekdays and one weekend day), 
together with the number of different food items habitually eaten, and whether the diet was 
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supplemented in any way or limited by special diet or by faddiness (arbitrary and often 
unusual likes and dislikes about food) diets as reported by their parents.   
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Gut Permeability 
Gut permeability was determined, following oral dosing with a mixture of lactulose and 
mannitol, as the urinary lactulose/mannitol (L/M) recovery ratio and lactulose recovery 
(percentage of oral dose administered), measured by electrospray mass spectrometry-mass 
spectrometry (MSMS). The differential sugar absorption test remains the primary objective 
test of gut permeability. It relies on the contrast between the almost complete absorption of 
the simple sugar alcohol, mannitol, and the virtually total exclusion, in normal individuals, of 
the disaccharide, lactulose, by the gut membrane. Neither mannitol nor lactulose is 
metabolised in the body, so that any absorbed is freely filtered by the kidney and appears in 
the urine. As a result, the permeability of the gut can be assessed, either by the lactulose 
recovery (percentage of oral dose administered) or by the ratio of the recovery of lactulose 
and mannitol, in an accurately timed urine collection. Accurate measurement of mannitol and 
particularly lactulose are crucial. In individuals with normal gut permeability the L/M 
recovery ratio is usually <0.03 [Wyatt, Vogelsang, Hubl, Waldhoer, & Lochs, 1993] and the 
lactulose recovery is usually <0.5% of the dose [D’Eufemia et al., 1996; Marsilio, D’Antiga, 
Zancani, Dussini, & Zacchello, 1998]. In severe active inflammatory bowel disease (IBD) the 
lactulose recovery may exceed 5% and the L/M recovery ratio may exceed 0.25 [Marsilio, 
D’Antiga, Zancani, Dussini, & Zacchello, 1998]. Although the true sensitivity of the test has 
not been formally assessed, even in mild IBD [Halme, Turunen, Tuominen, Forsstrom, & 
Turpeinen, 2000]
 and coeliac disease [Marsilio, D’Antiga, Zancani, Dussini, & Zacchello, 
1998], the mean L/M recovery ratio is increased.  
 
Participants were advised to have nothing to eat or drink after midnight. Immediately 
following early morning urine voiding, participants were given a mixture of mannitol (2g, 
11.0 mmol) and lactulose (5g, 14.6 mmol) orally. They were advised to drink plenty of water. 
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In an attempt to ensure there was no food in the intestinal lumen that might interfere with the 
test, but acknowledging that it was unrealistic to expect families to travel the distance from 
home to hospital with water only,  participants were advised to have no more than a slice of 
toast an hour later.  All urine was then collected for approximately 6 hours, in a pre-weighed 
urine collection bottle containing 0.2g thiomersal, with a final voiding as close to 6 hours as 
possible. The urine collection bottle was re-weighed, to determine the volume of urine, before 
storage in 2 x 4 ml aliquots at -80
o
C until analysis. Lactulose and mannitol were measured in 
both the pre and 6 hours urine samples by MSMS by laboratory investigators who were blind 
to the diagnostic status of the participants. 
 
Data Analysis 
All analyses were undertaken in Stata 9 (Stata Corporation, 2005). Group differences were 
examined between children with ASD and those with SEN; within the ASD group, between 
those with and without regression, using the test command of stata. Sample weights were 
used in all analyses to allow all statistics such as proportions, means, and group differences to 
be presented as target population estimates, taking into account not only the differences in 
sampling proportions and the differential response to the SCQ screening questionnaire 
associated with a prior clinical ASD diagnosis, health district and child’s sex, but also the 
differential take up of the gut permeability test.  Standard errors of simple means, linear 
regressions, adjusted Wald test statistics and p-values were calculated using the linearization 
version of the robust parameter covariance matrix as implemented by the svy procedures of 
stata.  
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Results 
Of the 255 participants, 158 met consensus ASD diagnosis. The other 97 had special 
educational needs (SEN) with a variety of other diagnoses and did not meet criteria for a 
diagnosis of ASD. All children were approached for consent to participate in the gut 
permeability test but some were unable to do so. The main reasons for failure to participate 
concerned individual consent and test procedure: reliable bladder emptying on demand, 
difficulty in getting some children to drink the mannitol/lactulose mixture and difficulty 
collecting 6 hours of urine, often while in transit. Gut permeability was measured in 103 with 
ASD and 30 with SEN (14 had a learning disability, 3 had a language disorder, 3 had a 
hearing impairment, 7 had hyperkinetic or conduct disorders, 2 had a chromosome disorder, 
and 1 had no clinical diagnosis). The participants’ IQ ranged from 51 to 131 (SEN) and 28 to 
136 (ASD).  A comparison of those who participated in the gut permeability study with those 
who did not, showed that participants were younger (t (249) = 7.34, p<.001), had higher IQ (t 
(251) = -3.63, p <.001) and greater ASD severity (t (253) = -4.23, p<.001) than non-
participants. Regression was reported in 20 of the ASD group; 83 had no history of 
regression. Group characteristics are summarised in Table 1.  
 
Weighted mean scores for urine creatinine recovery, mannitol recovery, lactulose/mannitol 
(L/M) recovery ratio and lactulose recovery are presented in Table 2 and Figures 1-4. The 
recovery of urine creatinine was not significantly different in the ASD and SEN groups 
(t(101)=0.00, p = .98). Similarly, there was no significant difference (t(101)=0.32, p =.76) 
between the ASD group with regression and the ASD group without regression. 
 
The recovery of urine mannitol, percentage of oral dose, was not significantly different in the 
ASD and SEN patient groups (t(131)=0.52, p =.60). Similarly, there was no significant 
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difference (t(101)=1.05, p=0.30) between the ASD group with regression and the ASD group 
without regression. 
 
As expected, there was a highly significant relationship between the recovery of creatinine 
and mannitol (β=2.53 (SE=0.77); t(131)=3.28,  p <.005) but no significant association 
between the recovery of creatinine and lactulose (=0.02 (SE=0.01); t(131)=1.15, p =.25). 
Critically, there was no correlation between the recovery of creatinine and the L/M recovery 
ratio (=-0.001 (SE=0.0009); t(131)=1.56, p = .12), indicating that the latter was independent 
of the completeness of urine collection. 
 
Analysis of the gut permeability indices demonstrated no significant differences between the 
ASD and SEN patient groups for either the L/M recovery ratio (t(131)=0.56, p=.56) or the 
lactulose recovery (percentage of oral dose) (t(131)=1.26,  p=.21).  
 
There was no significant difference (p=.36) for the L/M recovery ratio between the ASD 
group with regression and the ASD group without regression. In addition, there was no 
significant difference (p=.46) for the lactulose recovery between the ASD group with 
regression and the ASD group without regression.   
 
Within the ASD group, there was no relationship between L/M recovery ratio and autism 
severity as measured either by number of ICD-10 symptoms (t(101)=1.70, p = .93) or ADOS-
G severity scores (t(101)= 1.10, p = .28).  Similarly, no relationship was found between 
lactulose recovery and ICD-10 symptoms (t(101)=1.35, p = .18) or between lactulose 
recovery and ADOS-G severity scores (t(101)=0.94, p = .35). 
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The GI symptom questionnaire was completed by 126 parents of the 133 children who had 
permeability measured.  Mean unweighted current and past GI symptom counts are presented 
in Table 3, as are the rates of current and past vomiting, abdominal pain and diarrhoea.   
None of the children had GI symptoms that met the enterocolitis definition.  Abdominal pain 
was the most frequently reported symptom currently and in the past. It was only moderately 
correlated with constipation (constipation measured by reported decreased frequency of 
bowel action r =.42, p<.0001; and when measured by decreased frequency, difficulty in 
passing stool or hardness of stool r =.50, p<.0001) 
Diet 
Sufficiently detailed parental information on food selectivity for analysis was available on 
only 46 participants who also completed the gut permeability test (12 SEN, 34 ASD) and who 
had also completed the GI symptom questionnaire.  Those who completed the diet 
questionnaire did not differ from those who did not in terms of  IQ, ICD-10 score, current or 
past reported GI symptoms (all p >.32).  A ‘limited’ diet was defined as less than 10 food 
items in the diet; two parents reported diets with fewer than 5 food items (one with ASD and 
the other SEN without ASD). A limited diet was reported in 3/12 SEN cases (25%) and 14/34 
(41%) ASD cases (no significant difference, Pearson chi2, p = 0.318).  A faddy diet was 
reported in 4/12 (33%) SEN and 10/34 (29%) ASD cases.  A limited or faddy diet did not 
account for any of the group differences found in relation to GI symptoms.  
 
Adequate blood samples were collected from 63 of the children who had gut permeability 
measured; one child with ASD had positive endomysial antibodies and was subsequently 
diagnosed on retest and confirmatory mucosal biopsy as having coeliac disease. 
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No significant correlations were found between L/M recovery ratios and current or past GI 
symptom counts (r = -0.07, p = .45; r =0.07, p = .44) or between lactulose recovery and 
current or past GI symptom counts (r = -0.04, p = .68; r = 0.08, p = .38).  No significant 
associations were found between individual GI symptoms and either raised lactulose recovery 
(>0.5%) or raised L/M recovery ratios (>0.03, Fisher’s Exact p all >.1).  No significant 
associations were found between restricted or faddy diets and either raised L/M ratios or 
raised lactulose recovery.  
 
Eleven participants (9 ASD, 2 SEN) had an L/M recovery ratio >0.03, but only two of these, 
1 ASD, 1 SEN,  had a recovery ratio >0.04. The child with ASD had no GI symptoms but 
was found to have undiagnosed coeliac disease. The child with SEN had current diarrhoea 
and past persistent vomiting, a history of gastroschisis and had had several surgical 
procedures including excision of part of the small bowel. Of the other 9, two had no 
gastrointestinal symptoms, six reported past diarrhoea (only one reported diarrhoea for more 
than 14 days) and one reported current diarrhoea of less than 14 days. Ten children (7 ASD, 2 
SEN) had lactulose recovery between 0.5 and 1%, only 4 >0.6%.  
 
Five of 133 children (4 ASD, 1 SEN) had both a raised lactulose recovery (>0.6%) and a 
raised L/M recovery ratio >0.03, of whom two had a lactulose recovery >0.6% and L/M ratio 
>0.04 (1 ASD and 1 SEN), as reported above.  
 
Discussion 
In the present study we have compared children with ASD with an age and IQ-matched group 
of children with SEN but without ASD. We found no evidence of increased gut (small bowel) 
permeability in children with ASD compared with  children with SEN. This remained the 
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case even when the ASD group was sub-categorised into those patients with and without 
evidence of regression. Using the “gold standard” measure of gut permeability, the mean L/M 
recovery ratios and 95% confidence intervals were equivalent in the ASD and SEN groups 
and well within the normal range.  Gastrointestinal symptoms, abdominal pain, constipation, 
vomiting and diarrhoea were reported in a significant number of participants (also 
reported in Chandler et al) but there was no association found between the 
presence of gut symptoms and gut permeability measures.  
 
Robertson and co-investigators [Robertson, Sigalet, Holst, Meddings, Wood, & Sharkey, 
2008] reported that L/M recovery ratios were not significantly different in 14 patients with 
ASD: 0.032 (0.015), 7 siblings: 0.039 (0.016), and 8 control children: 0.031 (0.015). The 
mean values are all greater than 0.03, but this may reflect the use of 12h overnight urine 
collections.  In contrast, Horvath and colleagues [Horvath, Zielke, Collins, Rabsztyn, 
Medeiros, & Perman, 2000] described increased L/M recovery ratios in 19/25 children with 
autism and gastrointestinal symptoms, but there was no appropriate control group.  
D’Eufemia et al. [1996] reported no overall difference in mean lactulose recovery when 
comparing 21 patients with autism (but no evidence of gastrointestinal disorders) with 40 
controls (mean lactulose recovery 0.38%). However, 9 of the 21 patients had increased 
lactulose recoveries (>0.5%; mean 1.64%), compared with none of the 40 controls, 
suggesting significantly increased gut permeability in a sub-group of children with ASD. De 
Magistris et al. [2010]
 
reported that 33 out of 90 ASD patients had an L/M recovery ratio 
>0.03, mean L/M recovery 0.041, SD 0.08.  SD at twice the mean indicates a skewed 
distribution and, therefore, might suggest at least a few patients with pathological 
gastrointestinal permeability problems. Interestingly, there was no correlation between L/M 
recovery ratio and faecal calprotectin, a marker of intestinal inflammation. Although the L/M 
ratio, mean (SD), was only 0.028 (0.05) in 138 first degree relatives, 31 also had a ratio 
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>0.03. In 8 siblings the mean (SD) was 0.051 (0.06), again the high SD suggesting that, in the 
single sibling with a ratio >0.03, there was severe gastrointestinal leakiness. De Magistris et 
al. [2010] also reported that mean lactulose recovery was 0.57% in 90 patients with ASD 
with a standard deviation (SD) of 0.8, indicating that a significant number had markedly 
increased gut permeability. Surprisingly, the recoveries were even higher and more variable 
in first degree relatives (n=138, mean (SD) = 0.60 (0.7)) and siblings (n=8, mean (SD) = 1.62 
(1.6)), leading the authors to suggest the possibility of an inherited gut permeability 
abnormality in families with children with autism. In our study, in 11 of 133 participants 
tested (9 ASD, 2 SEN) L/M recovery ratios were marginally increased compared with the 
generally accepted upper limit and 10 had increased lactulose recovery. Five had both a 
raised L/M ratio and raised lactulose recovery. Significantly, two participants (1 ASD, 1 
SEN) had a recovery ratio >0.04 (a more obviously pathological figure) and raised lactulose 
recovery and both had gastrointestinal pathology. The child with ASD had no GIS but had 
undiagnosed coeliac disease confirmed with biopsy; the child with SEN had past GIS and had 
had gastroschisis requiring bowel excision operations.  
 
There are obvious disparities in the results and conclusions of the current study and those 
presented by Robertson and colleagues [Robertson, Sigalet, Holst, Meddings, Wood, & 
Sharkey, 2008], when compared to the previous studies reporting increased gut permeability 
in children with ASD [De Magistris et al., 2010; D’Eufemia et al., 1996; Horvath, Zielke, 
Collins, Rabsztyn, Medeiros, & Perman, 2000]. The protocols for the studies are very similar; 
the 12h overnight collection [Robertson, Sigalet, Holst, Meddings, Wood, & Sharkey, 2008]  
has already been highlighted, but all the studies used the maximum 2g of lactulose 
recommended [Bjarnason, MacPherson, & Hollander, 1995].  
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Analytical problems, particularly with respect to the measurement of lactulose in the presence 
of lactose, cannot be discounted as it is not stated in any of the studies that lactose was 
restricted before the studies were performed. We optimised the chromatography to separate 
lactose and lactulose and then tested our chromatographic system at the start and end of each 
analytical run to ensure the separation was maintained; the normal and spiked internal quality 
control samples both contained significant lactose.  Obviously any method failing to separate 
lactose and lactulose will lead to artefactual increases in measured lactulose and this cannot 
be ruled out as an explanation of difference in results. 
 
The possibility that severity of the disorder or regression might explain the differing results 
between studies is addressed by the lack of any evidence of increased gut permeability with 
severity of autism as measured by ICD-10 scores and autism versus other ASD diagnoses or 
in the sub-analysis of ASD with and without evidence of regression.  
 
The possibility that there was transient permeability of the gut at a younger age cannot be 
ruled out.  
Limitations of this study are the small number of children with SEN, the limited number with 
dietary information, the fact that a number of children and families did not manage to 
participate in the permeability test and the absence of a group of typically developing 
children. The latter would have enabled an additional control group for the measurement 
technique and further delineation of the normal range of the L/M ratio, particularly the upper 
limit of normal. The two definitely abnormal permeability results obtained were linked to 
clear gastrointestinal pathology (neither known to the laboratory). A further limitation is that 
the GIS questionnaire is not validated,  GI symptoms were elicited by parent report and not 
by a gastroenterologist thus we cannot distinguish eg abdominal pain due to constipation or 
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some other cause.  However Gorrindo et al’s study shows high concordance between parent  
and gastroenterologist for the presence of GIS if not specificity of a particular diagnosis.  
 Strengths of the study are that this is a large sample for this kind of study with a wide range 
of IQ, that it is derived from a population cohort, and that the measurement technique was 
accurate particularly in ensuring lactose and lactulose separation. Obtaining 6 hour samples 
from children with autism is not easy and complete emptying of the bladder cannot be 
guaranteed. As reported, however, there was no correlation between the recovery of 
creatinine and the L/M recovery ratio, indicating that the latter was independent of the 
completeness of urine collection. We conclude that the data in the current study provide no 
evidence for differentially increased small bowel gut permeability in children with autism at 
the age of 10-12 years and, despite the reported gastrointestinal problems, provide no support 
for a persistent ‘leaky’ gut in children.  
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Table 1: Group characteristics in terms of weighted mean scores, linearized standard errors 
(LSE) and 95% confidence intervals (CI) for age, IQ, number of ICD-10 symptoms and 
numbers of males and females 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SEN controls 
(N=30) 
 
ASD 
(N=103) 
 ASD, no 
regression 
(N=83) 
ASD and 
regression (N=20) 
Age in years (LSE) 
CI 
12.59 (0.31) 
11.98-13.20 
11.44 (0.11) 
11.22-11.65 
 11.45 (0.13) 
11.20-11.70 
11.39 (0.15) 
11.09-11.69 
IQ  (LSE) 
CI 
77.75 (3.38) 
71.06-84.44 
74.65 (2.68) 
69.35-79.95 
 75.63 (3.19) 
69.29-81.96 
69.94 (2.73) 
64.52-75.36 
ICD-10 total (LSE) 
CI 
1.68 (0.31) 
1.07-2.23 
7.17 (0.34) 
6.50-7.84 
 6.94 (0.34) 
6.28-7.61 
8.29 (1.23) 
5.85-10.74 
Males, females 26, 4 89, 14  71, 12 18, 2 
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Table 2: Weighted mean scores (LSE) and 95% confidence intervals (CI) of urine creatinine recovery (mmol) (UCR), urine mannitol 
recovery (percentage of oral dose) (UMR), and the gut permeability indices urine lactulose/mannitol (L/M) recovery ratio and lactulose 
recovery (percentage of oral dose administered) (LR) across diagnostic groups  
 
 SEN controls 
(N=30) 
ASD 
(N=103) 
Adj Wald 
Test 
p 
 ASD, no 
regression 
(N=83) 
ASD and 
regression 
(N=20) 
Adj Wald 
Test 
p 
UCR  
CI 
2.07 (0.15) 
1.78-2.37 
2.07 (0.11) 
1.85-2.28 
0.98  2.08 (0.12) 
1.84-2.32 
2.00 (0.25) 
1.50-2.49 
0.76 
UMR 
CI 
18.23 (1.43) 
15.40-21.06 
19.20 (1.20) 
16.83-21.58 
0.60  19.71 (1.31) 
17.10-22.31 
16.82 (2.40) 
12.06-21.58 
0.29 
L/M 
CI 
0.01 (0.003) 
0.01-0.02 
0.02 (0.001) 
0.01-0.02 
0.56  0.01 (0.001) 
0.01-0.02 
0.02 (0.01) 
0.01-0.03 
0.36 
LR 
CI 
0.22 (0.03) 
0.16-0.29 
0.27 (0.03) 
0.24-0.30 
0.21  0.27 (0.02) 
0.23-0.30 
0.29 (0.05) 
0.18-0.40 
0.67 
 28 
Table 3: Mean (standard deviation) GI composite symptom counts, and proportions of endorsed individual 
GI symptoms for SEN controls and ASD cases 
 
 SEN controls  
(N=29
a
) 
ASD 
 (N=97
 a
) 
Composite current GI symptoms 
Mean (SD) 
 
0.18 (0.50)* 
 
0.54 (0.89)* 
Individual current symptoms % (N) % (N) 
Persistent vomiting 3.5 (1) 2.1 (2) 
Abdominal pain 3.5 (1) 16.7 (16) 
Diarrhoea 5.9 (1) 2.9 (2) 
Constipation
 
(decrease in freq) 
b
 
Constipation (any of 3 symptoms) 
c
 
3.7 % (1) 
3.7 % (1) 
9.9 % (9) 
11.3 % (11) 
Composite past GI symptoms    
Mean (SD) 0.23 (0.54)* 0.61 (0.90)* 
Individual past symptoms % (N) % (N) 
Persistent vomiting 7.1 (2) 13.4 (13) 
Abdominal pain 6.9 (2)) 19.0 (18) 
Diarrhoea 5.0 (1) 18.9 (14) 
 
a
 Total Ns for cell proportions vary slightly, depending on amount of missing data, largely due to ‘do not 
know’ responses on individual items of questionnaire. 
b 
Constipation
 
defined as a decrease in frequency of passing a bowel motion (to less than 3 times a week) 
c
 Constipation defined as either a decrease in frequency of bowel movement, or a harder consistency of 
bowel movement, or difficulty in passing a bowel movement 
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* p<.05 
 
Table 3: Mean (standard deviation) GI composite symptom counts, and proportions of endorsed individual 
GI symptoms for SEN controls and ASD cases 
 
 SEN controls  
(N=29
a
) 
ASD 
 (N=97
 a
) 
Composite current GI symptoms 
Mean (SD) 
 
0.18 (0.50)* 
 
0.54 (0.89)* 
Individual current symptoms % (N) % (N) 
Persistent vomiting 3.5 (1) 2.1 (2) 
Abdominal pain 3.5 (1) 16.7 (16) 
Diarrhoea 5.9 (1) 2.9 (2) 
   
Composite past GI symptoms    
Mean (SD) 0.23 (0.54)* 0.61 (0.90)* 
Individual past symptoms % (N) % (N) 
Persistent vomiting 7.1 (2) 13.4 (13) 
Abdominal pain 6.9 (2)) 19.0 (18) 
Diarrhoea 5.0 (1) 18.9 (14) 
 
a
 Total Ns for cell proportions vary slightly, depending on amount of missing data, largely due to ‘do not 
know’ responses on individual items of questionnaire. 
* p<0.05 
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Figure Legends 
 
Figure 1:  Creatinine recovery (mmol) by diagnostic group as raw (unweighted) data; 
boxplots indicate median, lower and upper quartiles, and outliers 
 
Figure 2: Mannitol recovery (% of dose) by diagnostic group as raw (unweighted) data; 
boxplots indicate median, lower and upper quartiles, and outliers 
 
Figure 3:  Lactulose/mannitol recovery ratios by diagnostic group as raw (unweighted) data, 
with cut-off indicating upper level of normal range; boxplots indicate median, lower and 
upper quartiles, and outliers 
 
Figure 4:  Lactulose recovery (% of dose) by diagnostic group as raw (unweighted) data, 
with cut-off indicating upper level of normal range; boxplots indicate median, lower and 
upper quartiles, and outliers 
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Appendix  
Details of laboratory methodology: 
Mixed lactulose (100, 500, and 1000 µmol/l) and mannitol (1, 5 and 10 mmol/l) standards 
were prepared in deionised water and stored, in aliquots, at -80
o
C. Spiked urine controls, 
lactulose (50 and 700 µmol/l) and mannitol (0.5 and 7.0 mmol/l) were prepared and stored, in 
aliquots, at -80
o
C. For analysis, standards, controls, and samples were thawed, vortex mixed, 
centrifuged at 1500 rpm and 4
o
C for 4 min, 10 µl diluted to 500 µl with deionised water, 
transferred to a 96 deep well polypropylene plate, sealed, and placed in a CTC autosampler 
maintained at 10
o
C. Chromatography was performed isocratically on an Agilent ZorbaxNH2 
carbohydrate analysis column (25 cm x 2.1 mm, packed by Hichrom, UK) with acetonitrile: 
water as mobile phase (200 µl/min). The ratio varied between 75 and 80% acetonitrile to 
optimise the separation of lactulose and lactose: inject to inject time was approximately 20 
min. MSMS was performed in negative ion mode (-4200 V) on a SCIEX API4000 triple 
quadrupole mass spectrometer (Applied Biosystems, UK). Three experiments were 
performed (150 ms/scan) in multiple reaction monitoring (MRM) mode for disaccharides 
(m/z 340.9/160.9), hexitols (m/z 181.0/88.9), and hexoses (m/z 178.9/89.0) (data not 
included). Each MRM was optimised for maximum signal:noise ratio using aqueous 
lactulose, mannitol, and glucose standards, respectively. Results were calculated using 
Analyst 1.3.1 or 1.4.1. The lactulose response was linear over the range 0 to 1000 µmol/l but 
the mannitol response over the range 0 to 10 mmol/l was best represented by a quadratic 
function. Measured mannitol concentrations >10 mmol/l were re-diluted 1:200 with deionised 
water and re-analysed. Within-assay reproducibility (n=5), assessed using the spiked control 
samples, was 8.4% (53.5 µmol/l) and 9.3% (678 µmol/l) for lactulose and 6.1% (0.59 
mmol/l) and 9.3% (7.28 mmol/l) for mannitol. Between-assay reproducibility (n=21) was 
8.7% (53.5 µmol/l) and 13.8% (689 µmol/l) for lactulose and 5.5% (0.58 mmol/l) and 9.8% 
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(7.09 mmol/l). The possibility of ion suppression in patient samples was tested by analysing 
several samples at dilutions ranging from 1:5 to 1:200, but no suppression was detected. 
Urine creatinine was measured using a modified stable isotope dilution MSMS method
32
, to 
assess completeness of the urine collections and to correct for any interference in the pre-dose 
samples. Correction reduced the average L/M recovery ratio from 0.0156 to 0.0154 and the 
average lactulose recovery from 0.289 to 0.278%. 
 
 
